Christin Ungewiss

TL;DR: A molecular link between epithelial-to-mesenchymal transition (EMT) and CD8+ TIL immunosuppression and cancer progression is demonstrated and ZEB1 promotes metastasis through a heretofore unappreciated cell non-autonomous mechanism, and subgroups of patients in whom malignant progression is driven by EMT activators may respond to treatment with PD-L1 antagonists.

TL;DR: It is observed that tumors treated with PD-1/PD-L1 blocking antibodies develop resistance through the upregulation of CD38, which is induced by all-trans retinoic acid and IFNβ in the tumor microenvironment, providing a novel mechanism of acquired resistance to immune checkpoint therapy.

TL;DR: Results reveal how expression of miR-200 alters the tumor microenvironment to inhibit the processes of EMT and metastasis.

TL;DR: It is demonstrated that CRKL serves as an adaptor molecule to facilitate focal adhesion formation, mediates outside-in signaling through Itgβ1 to drive cell invasion, and inside-out signaling that maintains tumor cell-matrix contacts required for cell invasion.

TL;DR: An Ex Vivo Tumor platform to culture tumors in 3D matrices is developed and Src signaling is identified as an important driver of invasion and metastasis in lung cancer and EVTs are a robust experimental tool bridging the gap between conventional in vitro and in vivo models.